The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
ID: ALA4161994
Max Phase: Preclinical
Molecular Formula: C19H15FN2O3
Molecular Weight: 338.34
Molecule Type: Small molecule
Associated Items:
Representations Canonical SMILES: Cc1noc(C)c1-c1ccc2c(c1)OC(c1ccccc1F)C(=O)N2
Standard InChI: InChI=1S/C19H15FN2O3/c1-10-17(11(2)25-22-10)12-7-8-15-16(9-12)24-18(19(23)21-15)13-5-3-4-6-14(13)20/h3-9,18H,1-2H3,(H,21,23)
Standard InChI Key: CBMLEDNBJXYMIV-UHFFFAOYSA-N
Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Properties Molecular Weight: 338.34Molecular Weight (Monoisotopic): 338.1067AlogP: 4.17#Rotatable Bonds: 2Polar Surface Area: 64.36Molecular Species: NEUTRALHBA: 4HBD: 1#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0CX Acidic pKa: 11.30CX Basic pKa: 1.42CX LogP: 3.18CX LogD: 3.18Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.76Np Likeness Score: -0.78
References 1. Xue X, Zhang Y, Wang C, Zhang M, Xiang Q, Wang J, Wang A, Li C, Zhang C, Zou L, Wang R, Wu S, Lu Y, Chen H, Ding K, Li G, Xu Y.. (2018) Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer., 152 [PMID:29758518 ] [10.1016/j.ejmech.2018.04.034 ]